论文部分内容阅读
目的:探讨肝素酶mRNA在非小细胞肺癌(non_small cell lung cancer,NSCLC)中的差异性表达及其临床和病理学特征。方法:分别选取100例肺癌(实验组)和60例肺良性病变(对照组)手术标本,用逆转录PCR检测肝素酶mRNA。结果:①肝素酶mRNA在NSCLC中表达率均高于良性病变肺组织(P<0.01)。②肝素酶mRNA表达率在淋巴结转移组,Ⅲ期+Ⅳ期组、低分化组、腺癌组、肿瘤最大直径≥5 cm组分别高于无淋巴结转移组、Ⅰ期+Ⅱ期组、鳞癌组、肿瘤最大直径<5 cm组(P<0.05)。③肝素酶mRNA表达率在不同性别、年龄组比较,差异无显著性(P>0.05)。结论:肝素酶参与了NSCLC侵袭转移过程,可作为评估肺癌的恶性程度、转移潜力以及判断预后的一个新的标记物。
Objective: To investigate the differential expression and clinical and pathological features of heparanase mRNA in non-small cell lung cancer (NSCLC). Methods: 100 cases of lung cancer (experimental group) and 60 cases of benign lung disease (control group) were selected for surgical specimens, heparinase mRNA was detected by reverse transcription PCR. Results: ① Heparinase mRNA expression in NSCLC was higher than that in benign lesions (P <0.01). ② Heparinase mRNA expression in lymph node metastasis group, stage Ⅲ + Ⅳ group, poorly differentiated group, adenocarcinoma group, the maximum tumor diameter ≥ 5 cm group were higher than those without lymph node metastasis, stage Ⅰ + Ⅱ group, Cancer group, tumor diameter <5 cm group (P <0.05). ③ Heparinase mRNA expression in different gender, age group, the difference was not significant (P> 0.05). Conclusion: Heparinase is involved in the process of NSCLC invasion and metastasis, which can be used as a new marker to evaluate the malignancy, metastasis potential and prognosis of lung cancer.